Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (16)
  • Open Access

    ARTICLE

    A Deep Learning Framework for Mass-Forming Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma Classification Based on Magnetic Resonance Imaging

    Luda Chen1, Kuangzhu Bao2, Ying Chen2, Jingang Hao2,*, Jianfeng He1,3,*

    CMC-Computers, Materials & Continua, Vol.79, No.1, pp. 409-427, 2024, DOI:10.32604/cmc.2024.048507

    Abstract Pancreatic diseases, including mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC), present with similar imaging features, leading to diagnostic complexities. Deep Learning (DL) methods have been shown to perform well on diagnostic tasks. Existing DL pancreatic lesion diagnosis studies based on Magnetic Resonance Imaging (MRI) utilize the prior information to guide models to focus on the lesion region. However, over-reliance on prior information may ignore the background information that is helpful for diagnosis. This study verifies the diagnostic significance of the background information using a clinical dataset. Consequently, the Prior Difference Guidance Network (PDGNet) is proposed, merging decoupled lesion… More >

  • Open Access

    REVIEW

    Targeting KRAS in pancreatic cancer

    SANDRA STICKLER, BARBARA RATH, GERHARD HAMILTON*

    Oncology Research, Vol.32, No.5, pp. 799-805, 2024, DOI:10.32604/or.2024.045356

    Abstract Pancreatic cancer has a dismal prognosis due to late detection and lack of efficient therapies. The Kirsten rat sarcoma virus (KRAS) oncogene is mutated in up to 90% of all pancreatic ductal adenocarcinomas (PDACs) and constitutes an attractive target for therapy. However, the most common KRAS mutations in PDAC are G12D (44%), G12V (34%) and G12R (20%) that are not amenable to treatment by KRAS G12C-directed cysteine-reactive KRAS inhibitors such as Sotorasib and Adagrasib that exhibit clinical efficacy in lung cancer. KRAS G12C mutant pancreatic cancer has been treated with Sotorasib but this mutation is detected only in 2%–3% of… More >

  • Open Access

    ARTICLE

    Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2

    HYUNG SUN KIM1,#, YUN SUN LEE2,#, SEUNG MYUNG DONG3, HYO JUNG KIM1, DA EUN LEE2, HYEON WOONG KANG2, MYEONG JIN KIM2, JOON SEONG PARK1,*

    Oncology Research, Vol.32, No.4, pp. 615-624, 2024, DOI:10.32604/or.2024.044029

    Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies. A specific mechanism of its metastasis has not been established. In this study, we investigated whether Neural Wiskott-Aldrich syndrome protein (N-WASP) plays a role in distant metastasis of PDAC. We found that N-WASP is markedly expressed in clinical patients with PDAC. Clinical analysis showed a notably more distant metastatic pattern in the N-WASP-high group compared to the N-WASP-low group. N-WASP was noted to be a novel mediator of epithelial-mesenchymal transition (EMT) via gene expression profile studies. Knockdown of N-WASP in pancreatic cancer cells significantly inhibited cell invasion, migration,… More > Graphic Abstract

    Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2

  • Open Access

    ARTICLE

    Meiotic nuclear divisions 1 suppresses the proliferation and invasion of pancreatic cancer cells via regulating H2A.X variant histone

    DONGQIN WANG1,4, YAN SHI1, ZHIQIANG WANG4, JING ZHANG2, LUYAO WANG2, HONGYU MA3, SHUHUA SHI2, XIAOFU LIAN2, HUA HUANG4, XIAOJING WANG1,*, CHAOQUN LIAN4,*

    BIOCELL, Vol.48, No.1, pp. 111-122, 2024, DOI:10.32604/biocell.2023.046903

    Abstract Introduction: Among all malignant tumors of the digestive system, pancreatic carcinoma exhibits the highest mortality rate. Currently, prevention and effective treatment are urgent issues that need to be addressed. Methods: The study focused on meiotic nuclear divisions 1 (MND1), integrating data from the Gene Expression Profiling Interactive Analysis (GEPIA) database with prognostic survival analysis. Simultaneously, experiments at cellular level were employed to demonstrate the effect of MND1 on the proliferation and migration of PC. The small-molecule inhibitor of MND1 was used to suppress the migration of PC cells by knocking down MND1 using small interfering RNA (siRNA) in Patu-8988 and… More >

  • Open Access

    ARTICLE

    Pancreatic Cancer Data Classification with Quantum Machine Learning

    Amit Saxena1, Smita Saxena2,*

    Journal of Quantum Computing, Vol.5, pp. 1-13, 2023, DOI:10.32604/jqc.2023.044555

    Abstract Quantum computing is a promising new approach to tackle the complex real-world computational problems by harnessing the power of quantum mechanics principles. The inherent parallelism and exponential computational power of quantum systems hold the potential to outpace classical counterparts in solving complex optimization problems, which are pervasive in machine learning. Quantum Support Vector Machine (QSVM) is a quantum machine learning algorithm inspired by classical Support Vector Machine (SVM) that exploits quantum parallelism to efficiently classify data points in high-dimensional feature spaces. We provide a comprehensive overview of the underlying principles of QSVM, elucidating how different quantum feature maps and quantum… More >

  • Open Access

    ARTICLE

    Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data

    XUEFENG WANG1,#, SICONG JIANG2,#, XINHONG ZHOU3, XIAOFENG WANG4, LAN LI5, JIANJUN TANG1,*

    Oncology Research, Vol.31, No.5, pp. 697-714, 2023, DOI:10.32604/or.2023.029458

    Abstract Background: Pancreatic cancer is associated with high mortality and is one of the most aggressive of malignancies, but studies have not fully evaluated its molecular subtypes, prognosis and response to immunotherapy of different subtypes. The purpose of this study was to explore the molecular subtypes and the key genes associated with the prognosis of pancreas cancer patients and study the clinical phenotype, prognosis and response to immunotherapy using single-cell seq data and bulk RNA seq data, and data retrieved from GEO and TCGA databases. Methods: Single-cell seq data and bioinformatics methods were used in this study. Pancreatic cancer data were… More >

  • Open Access

    ARTICLE

    mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

    CHIWEN BU1,2, LIGANG ZHAO1, LISHAN WANG1, ZEQIAN YU1, JIAHUA ZHOU1,*

    Oncology Research, Vol.31, No.4, pp. 495-503, 2023, DOI:10.32604/or.2023.029309

    Abstract Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new era for targeted therapy for this disease. However, most pancreatic cancer patients carry wild-type BRCA1/2 with resistance to PARP inhibitors. Here, we reported that mammalian target of rapamycin complex 2 (mTORC2) kinase is overexpressed in pancreatic cancer tissues and promotes pancreatic cancer cell growth and invasion. Moreover, we found that knockdown of the mTORC2 obligate subunit Rictor sensitized… More > Graphic Abstract

    mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

  • Open Access

    ARTICLE

    Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer

    XIN LI1,2,#, WENKAI JIANG3,#, WANCHENG LI3,#, SHI DONG3, YAN DU3, HUI ZHANG1,*, WENCE ZHOU1,3,*

    Oncology Research, Vol.31, No.4, pp. 505-514, 2023, DOI:10.32604/or.2023.026959

    Abstract Background: The dilemma of pancreatic cancer treatment has become a global challenge. For this reason, effective, feasible, and new medical methods are currently much-needed. Betulinic acid (BA) has been valued as a potential therapy for pancreatic cancer. However, the mechanism by which BA exerts an inhibitory effect on the development of pancreatic cancer remains elusive. Methods: A rat model and two cell models of pancreatic cancer were established, and the effect of BA on pancreatic cancer was verified in vivo and in vitro by using MTT, Transwell, flow cytometry, RT-PCR, Elisa and immunohistochemistry. At the same time, miR-365 inhibitors were… More > Graphic Abstract

    Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer

  • Open Access

    REVIEW

    Progress on diagnostic and prognostic markers of pancreatic cancer

    HONG YANG1,2, WAN LI1,2, LIWEN REN1,2, YIHUI YANG1,2, YIZHI ZHANG1,2, BINBIN GE1,2, SHA LI1,2, XIANGJIN ZHENG1,2, JINYI LIU1,2, SEN ZHANG1,2, GUANHUA DU1,2, BO TANG3, HONGQUAN WANG3, JINHUA WANG1,2,*

    Oncology Research, Vol.31, No.2, pp. 83-99, 2023, DOI:10.32604/or.2023.028905

    Abstract Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate, whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed. Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens. So far, CA19-9 is the only biomarker for pancreatic cancer approved by the FDA, but its effectiveness is limited by low sensitivity and specificity. With recent advances in genomics, proteomics, metabolomics, and other analytical and sequencing technologies, the rapid acquisition and screening of biomarkers is now possible. Liquid biopsy also occupies a significant place due to… More > Graphic Abstract

    Progress on diagnostic and prognostic markers of pancreatic cancer

  • Open Access

    ARTICLE

    Columbianetin acetate inhibits the occurrence and development of pancreatic cancer cells by down-regulating the expression of Meiotic nuclear divisions 1

    KANG SUN1, DONGQIN WANG1, ZHIQIANG ZHANG1, YINLONG HUANG3, XIAOFU LIAN3, JIALE HUA3, JING ZHANG3,*, CHAOQUN LIAN1,2,*

    BIOCELL, Vol.47, No.2, pp. 297-307, 2023, DOI:10.32604/biocell.2023.023553

    Abstract Columbianetin acetate (CE) is one of the effective components of Angelica pubescens. So far, the specific role and molecular mechanism of CE in pancreatic cancer are not clear. Thus, this study aimed to explore the specific mechanism of CE on pancreatic cancer. The target genes combined with CE were predicted through the PharmMapper database and the 3D molecular structure of CE. Then, the Cancer Genome Atlas (TCGA) and Cistrome data browser (DB) databases were used to screen Meiotic nuclear divisions 1 (MND1)-related genes, transcription factors, and transcription factor data sets, and the intersection of the above data sets. The “limma”… More >

Displaying 1-10 on page 1 of 16. Per Page